Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antiviral granules
- Development stage
- Unknown
- Lead developer
- Jiangxi Wanji Pharmaceutical Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Yinma Antiviral Granules is a Chinese Patent Medicine (CPM) developed by Jiangxi Wanji Pharmaceutical, primarily indicated for the treatment of upper respiratory tract infections, including acute pharyngitis and acute catarrhal tonsillitis. The formulation is an oral granule composed of ten traditional Chinese medicinal herbs: *Lonicera japonica* (honeysuckle), *Forsythia suspensa*, *Isatis indigotica* (woad root), *Gypsum Fibrosum*, *Anemarrhena asphodeloides*, *Lycium chinense*, *Rehmannia glutinosa*, *Phragmites communis*, *Pogostemon cablin*, and *Acorus tatarinowii*. These ingredients are traditionally recognized for their heat-clearing and detoxifying properties. The drug works through a multi-target mechanism, exhibiting broad-spectrum antiviral activity against respiratory viruses and anti-inflammatory effects by inhibiting the release of pro-inflammatory cytokines such as TNF-alpha and IL-6. It is widely used in clinical practice in China to alleviate symptoms like fever, sore throat, and inflammation associated with viral infections.
- Brand names
- Yinma银马
- Other names
- Kangbingdu KeliYinma Antiviral GranulesYinma Kangbingdu Keli
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)
Beyond the preview
Go deeper on antiviral granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antiviral granules.